Skip to main content
. 2013 Jan 25;2013:bcr2012008142. doi: 10.1136/bcr-2012-008142

Figure 1.

Figure 1

Fluid-attenuated inversion recovery images approximately 3 weeks after the last rituximab administration showing hyperintense lesions in the thalamus/mesencephalon on the left (A) and in the right subcortical frontal lobe (B) without gadolinium enhancement or oedema.